logo
Plus   Neg
Share
Email

GlycoMimetics Inc. (GLYC) Is Dropping After The Bell

GlycoMimetics Inc. (GLYC) announced after the close Monday that it will launch its Phase 3 clinical trial to evaluate GMI-1271 in patients with relapsed/refractory acute myeloid leukemia in the third quarter of 2018.

GlycoMimetics declined until around 1:30PM Monday, before staging a bit of a recovery. The stock finished with a loss of 1.43 at $22.82. GlycoMimetics is now down 4.30 on 147K shares after the bell.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT